The use of multi-gene panels such as F1LCDx enables identification of other alterations within colorectal cancer (e.g., KRAS) or across tumor types (e.g., NTRK1/2/3) which are relevant to diagnosis and potential treatment options for patients (21, 22). This evidence concerns the gene NTRK1 and colorectal cancer.